Concepts (104)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoma | 11 | 2023 | 72 | 6.240 |
Why?
|
| Bone Neoplasms | 10 | 2023 | 122 | 4.600 |
Why?
|
| Soft Tissue Neoplasms | 5 | 2022 | 27 | 2.060 |
Why?
|
| Retrospective Studies | 16 | 2023 | 3062 | 1.360 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2023 | 175 | 1.130 |
Why?
|
| Giant Cell Tumor of Bone | 3 | 2022 | 15 | 0.950 |
Why?
|
| Margins of Excision | 2 | 2022 | 27 | 0.880 |
Why?
|
| Lymphatic Metastasis | 2 | 2021 | 81 | 0.860 |
Why?
|
| Chondrosarcoma | 1 | 2023 | 42 | 0.830 |
Why?
|
| Spinal Neoplasms | 1 | 2023 | 33 | 0.830 |
Why?
|
| Embolization, Therapeutic | 1 | 2023 | 41 | 0.820 |
Why?
|
| Kidney Neoplasms | 1 | 2023 | 62 | 0.810 |
Why?
|
| Neutrophils | 1 | 2023 | 85 | 0.800 |
Why?
|
| Sarcoma, Synovial | 1 | 2022 | 6 | 0.760 |
Why?
|
| Humans | 23 | 2023 | 22848 | 0.750 |
Why?
|
| Prognosis | 7 | 2023 | 630 | 0.750 |
Why?
|
| Lymphatic Vessels | 1 | 2021 | 9 | 0.710 |
Why?
|
| Myxosarcoma | 1 | 2020 | 3 | 0.700 |
Why?
|
| Osteosarcoma | 1 | 2021 | 33 | 0.700 |
Why?
|
| Fibrosarcoma | 1 | 2020 | 4 | 0.700 |
Why?
|
| Prosthesis-Related Infections | 1 | 2022 | 182 | 0.650 |
Why?
|
| Osteoarthritis | 1 | 2022 | 308 | 0.580 |
Why?
|
| Arthroplasty, Replacement, Hip | 2 | 2022 | 749 | 0.570 |
Why?
|
| Arthroplasty, Replacement, Knee | 2 | 2022 | 585 | 0.490 |
Why?
|
| Treatment Outcome | 6 | 2023 | 2960 | 0.480 |
Why?
|
| Child | 4 | 2021 | 990 | 0.450 |
Why?
|
| Survival Rate | 4 | 2021 | 270 | 0.410 |
Why?
|
| Limb Salvage | 2 | 2023 | 11 | 0.400 |
Why?
|
| Young Adult | 5 | 2021 | 1721 | 0.400 |
Why?
|
| Adolescent | 4 | 2021 | 1775 | 0.400 |
Why?
|
| Neoadjuvant Therapy | 3 | 2022 | 50 | 0.390 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2022 | 34 | 0.370 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2022 | 36 | 0.370 |
Why?
|
| Adult | 7 | 2022 | 6584 | 0.360 |
Why?
|
| Neoplasm Staging | 2 | 2022 | 307 | 0.350 |
Why?
|
| Proportional Hazards Models | 2 | 2021 | 270 | 0.330 |
Why?
|
| Follow-Up Studies | 4 | 2022 | 1494 | 0.330 |
Why?
|
| Middle Aged | 6 | 2021 | 7555 | 0.280 |
Why?
|
| Prospective Studies | 2 | 2023 | 1528 | 0.270 |
Why?
|
| Male | 7 | 2021 | 12453 | 0.230 |
Why?
|
| Female | 6 | 2021 | 12677 | 0.220 |
Why?
|
| Biopsy | 2 | 2023 | 181 | 0.220 |
Why?
|
| Curettage | 2 | 2022 | 9 | 0.220 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 4055 | 0.220 |
Why?
|
| Lower Extremity | 1 | 2023 | 29 | 0.210 |
Why?
|
| Surgical Flaps | 1 | 2023 | 44 | 0.210 |
Why?
|
| Blood Loss, Surgical | 1 | 2023 | 53 | 0.210 |
Why?
|
| Lymphocyte Count | 1 | 2023 | 14 | 0.210 |
Why?
|
| Bone Cements | 2 | 2022 | 82 | 0.210 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 16 | 0.210 |
Why?
|
| Lymphocytes | 1 | 2023 | 42 | 0.200 |
Why?
|
| Preoperative Care | 1 | 2023 | 102 | 0.200 |
Why?
|
| Lung Neoplasms | 2 | 2021 | 470 | 0.200 |
Why?
|
| Necrosis | 1 | 2022 | 21 | 0.200 |
Why?
|
| Infant | 2 | 2021 | 449 | 0.200 |
Why?
|
| Child, Preschool | 2 | 2021 | 489 | 0.200 |
Why?
|
| Plasma Gases | 1 | 2022 | 2 | 0.200 |
Why?
|
| Replantation | 1 | 2022 | 7 | 0.200 |
Why?
|
| Reoperation | 3 | 2022 | 846 | 0.200 |
Why?
|
| Femur | 2 | 2022 | 349 | 0.190 |
Why?
|
| Infant, Newborn | 2 | 2021 | 509 | 0.190 |
Why?
|
| Printing, Three-Dimensional | 1 | 2021 | 8 | 0.190 |
Why?
|
| Metastasectomy | 1 | 2021 | 4 | 0.190 |
Why?
|
| Time-to-Treatment | 1 | 2022 | 30 | 0.190 |
Why?
|
| Radiopharmaceuticals | 1 | 2022 | 45 | 0.180 |
Why?
|
| Aged | 4 | 2021 | 7669 | 0.180 |
Why?
|
| Positron-Emission Tomography | 1 | 2022 | 72 | 0.180 |
Why?
|
| Leiomyosarcoma | 1 | 2021 | 8 | 0.180 |
Why?
|
| Neoplasm Grading | 1 | 2021 | 42 | 0.180 |
Why?
|
| SEER Program | 1 | 2021 | 41 | 0.180 |
Why?
|
| Neoplasm Invasiveness | 1 | 2021 | 77 | 0.180 |
Why?
|
| Disease-Free Survival | 1 | 2021 | 138 | 0.170 |
Why?
|
| Hemipelvectomy | 1 | 2020 | 2 | 0.170 |
Why?
|
| Pelvic Neoplasms | 1 | 2020 | 9 | 0.170 |
Why?
|
| Ganglion Cysts | 1 | 2020 | 6 | 0.170 |
Why?
|
| Contracture | 1 | 2020 | 10 | 0.170 |
Why?
|
| Allografts | 1 | 2021 | 203 | 0.170 |
Why?
|
| Anti-Bacterial Agents | 1 | 2022 | 368 | 0.160 |
Why?
|
| Elbow Joint | 1 | 2020 | 113 | 0.150 |
Why?
|
| Tibia | 2 | 2010 | 231 | 0.150 |
Why?
|
| Time Factors | 1 | 2022 | 1220 | 0.150 |
Why?
|
| Hip Prosthesis | 1 | 2022 | 508 | 0.130 |
Why?
|
| Spinal Fusion | 1 | 2020 | 435 | 0.110 |
Why?
|
| Patellar Ligament | 1 | 2010 | 36 | 0.090 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2010 | 31 | 0.090 |
Why?
|
| Cell Division | 1 | 2022 | 72 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 36 | 0.050 |
Why?
|
| Apoptosis | 1 | 2022 | 172 | 0.050 |
Why?
|
| Pneumonectomy | 1 | 2021 | 53 | 0.050 |
Why?
|
| Lung | 1 | 2021 | 142 | 0.040 |
Why?
|
| Joint Capsule Release | 1 | 2020 | 10 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 214 | 0.040 |
Why?
|
| Mutation | 1 | 2021 | 284 | 0.040 |
Why?
|
| Elbow | 1 | 2020 | 44 | 0.040 |
Why?
|
| Prosthesis Design | 1 | 2022 | 448 | 0.040 |
Why?
|
| Prosthesis Failure | 1 | 2022 | 478 | 0.040 |
Why?
|
| Risk Factors | 1 | 2022 | 1942 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2021 | 1621 | 0.030 |
Why?
|
| Thoracoscopy | 1 | 2010 | 19 | 0.020 |
Why?
|
| Ilium | 1 | 2010 | 29 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2010 | 59 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2010 | 305 | 0.020 |
Why?
|
| Arthralgia | 1 | 2010 | 119 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2010 | 588 | 0.020 |
Why?
|